

Prior Authorization Criteria

Kentucky Medicaid

WEGOVY (SEMAGLUTIDE)

Approval Duration: 6 months for initial and renewal

Age Limit: ≥ 45 years of age

Quantity Limit: 4 pens per 28 days

- 1. INITIAL APPROVAL CRITERIA
- Being prescribed to lower the risk of death from cardiovascular causes, myocardial infarction, or stroke;
 AND
- Prescriber includes documentation (e.g., progress note) within the past year of pre-existing cardiovascular disease as defined by at least one of the following:
 - Previous myocardial infarction (MI); OR
 - Previous stroke (ischemic or hemorrhagic); OR
 - Symptomatic peripheral arterial disease:
 - Amputation due to atherosclerotic disease;
 - History of peripheral arterial revascularization procedure;
 - Intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest); AND
- Prescriber includes documentation (e.g., progress note) AND the patient has a claims history showing
 optimization on specified lipid-lowering therapy (e.g., moderate to high intensity statin, PCSK9) AND at
 least one of the following:
 - Beta-blocker: OR
 - RAS inhibitor such as an angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI); OR
 - Antiplatelet (e.g., aspirin, clopidogrel); OR
 - Prescriber has provided medical justification as to why the patient cannot use lipid-lowering therapies AND beta-blockers, RAS inhibitors, or antiplatelet therapies (provider must include dates of trial, if applicable); AND
- Patient has a body-mass index (BMI) of 27 kg/m² or greater; AND
- Prescriber includes documentation that the medication will be used in combination with a reduced calorie diet and increased physical activity; AND
- Patient does not have any of the following:
 - A history of diabetes;
 - Current A1c of 6.5% or higher;

AE = Age Edit CC = Clinical Criteria MD = Maximum Duration QL = Quantity Limit ST = Step Therapy





Prior Authorization Criteria

Kentucky Medicaid

- New York Heart Association (NYHA) class IV heart failure;
- End-stage kidney disease or dialysis;
- Plans to undergo coronary, carotid, or peripheral revascularization;
- No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method; AND
- The requested dose does not exceed the maximum FDA-approved dose; AND
- Not used in combination with another glucagon-like peptide (GLP-1) OR dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist.

2. RENEWAL CRITERIA

- Patient has not experienced any serious adverse effects, including development of pancreatitis; AND
- Patient does not have any of the following:
 - A history of diabetes;
 - Current A1c of 6.5% or higher;
 - New York Heart Association (NYHA) class IV heart failure;
 - End-stage kidney disease or dialysis;
 - o Plans to undergo coronary, carotid, or peripheral revascularization;
 - No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);
 - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method; AND
- Patient continues to use in combination with a reduced calorie diet and increased physical activity; AND
 - Prescriber verifies and includes documentation that patient has at least 5% reduction in baseline body weight; OR
 - Provider includes documentation assessing lifestyle and diet interventions if weight loss goal has not been met; AND
- Patient continues to use in concomitant therapy with cardiovascular disease therapy management; AND
- The requested dose does not exceed the maximum FDA-approved dose; AND
- Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist.

AE = Age Edit CC = Clinical Criteria MD = Maximum Duration QL = Quantity Limit ST = Step Therapy

